

## Synthesis, Characterization and Biological Activate 5-(Hydroxymethyl) Pyrrolidin-2-One at Room Temperature

Veerappan Jeyachandran<sup>1\*</sup>

<sup>1</sup>Department of Chemistry, Bharath Institute of Higher Education and Research, Selaiyur, Chennai, Tamil Nadu, India


\*Corresponding author e-mail: [jeyorg@gmail.com](mailto:jeyorg@gmail.com)

### ABSTRACT

#### Article Info

Volume 8, Issue 1  
 Page Number: 10-15  
 Publication Issue :  
 January-February-2021

A new class of chiral pyrrolidinone was synthesized from (5S)-5-[(trityloxy)methyl] pyrrolidin-2-one (6) (Schemes 1 and 2). The synthetic design followed led to the insertion of various substituents at 1 and 5 of the pyrrolidinone moiety. Some of them possess two or three stereo centers, here configuration was retained under the mild condition. The new compounds also carry an imidazole moiety, which, along with the 2-pyrrolidinone template, may prove pivotal to several biological processes.




The chiral pyrrolidinone (R) ring is incorporated in various compounds with biological and pharmaceutical activities [1]. Some of them are well known medicines, e.g., doxapram for patients with respiratory failure, piracetam for patients with Alzheimer's seizures, and senile dementia, concussion and other neurological problems [2,3]. The properties and applications of pyroglutamic acid as a versatile building block in asymmetric synthesis has extensively been reviewed in the literature [4,5]. Some of them exhibited anti-inflammatory and antihypertensive activity [6,7]

#### Article History

Accepted : 01 Jan 2021  
 Published : 06 Jan 2021

**Keywords:** Pyroglutamic Acid, Anti-Inflammatory, Doxapram And Alzheimer's Seizures



In recent years, we have designed and synthesized 2-pyrrolidinones, starting from the naturally derived 2-oxotetrahydropyrrol-5S-carboxylic acid, which is considered as a unique chiral synthon [8].


## Experimental

### GENERAL

The melting points were measured in open capillary tubes and are uncorrected. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on a Bruker (Avance) 300 MHz NMR instrument using TMS as internal standard and DMSO as solvent. Standard Bruker software was used throughout. Chemical shifts are given in parts per million ( $\delta$ -scale) and the coupling constants are given in Hertz [9]. Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyzer. Silica gel-G plates (Merck) were used for TLC analysis with a mixture of petroleum ether (60–80°C) and ethyl acetate as eluent. All the chemicals were purchased from Aldrich and used without any further purification.

### 1. Synthesis of ethyl-5-oxopyrrolidine (2)

In the present work, the reaction of pyroglutamic acid **1** (1 mmol) in EtOH was added drop wise  $\text{SOCl}_2$  (1.2 mmol). The resulting solution was stirred for overnight, the reaction was monitored by TLC, after completion of the reaction neutralized with saturated  $\text{NaHCO}_3$  and extracted with  $\text{CHCl}_3$ . The combined organics were dried ( $\text{Na}_2\text{SO}_4$ ) and the solvent was removed under reduced pressure to give a green oil which was purified by reduced pressure distillation to afford ethyl-5-oxopyrrolidine **2** (82%) as a white solid by known literature method [10].




Scheme 1. Synthesis of ethyl-5-oxopyrrolidine **2**

Isolated as green oil; Yield 82%;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.31 (t, 3H,  $J = 7.0$ ), 2.27–2.15 (m, 1H), 2.52–2.32 (m, 3H), 4.24 (q, 2H,  $J = 7.0$ ), 4.29–4.17 (m, 1H) and 7.23 (br s, 1H, NH).

## 2. Synthesis of ethyl-5-oxopyrrolidine (3)

Sodium borohydride (1 mmol) was added portion wise, over 15 min, to a solution of ethyl-2-pyrrolidinone-5-carboxylate **2** (1 mmol) in ethanol. The reaction mixture was allowed to stir at room temperature for additional 2-4 h. After completion of the reaction HCl (12 M) was added to the reaction mixture and the resulting mixture was filtered. The filtrate was concentrated in vacuum to give crude ethyl-5-oxopyrrolidine **3**, which was used for the next step [10].



Scheme 2. Synthesis of ethyl-5-oxopyrrolidine **3**

Isolated as colourless oil; Yield 80%;  $^1\text{H NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  1.75–1.83 (m, 1H), 2.10–2.21 (m, 1H), 2.31–2.44 (m, 2H), 3.45 (dd,  $J=11.0, 6.8$ , 1H), 3.73 (dd,  $J=11.0, 3.1$ , 1H), 3.80 (m, 1H), 4.56 (br s, 1H), 7.60 (br s, 1H).




Figure 1.  $^1\text{H NMR}$  spectrum of **2**




Figure 3.  $^1\text{H}$  NMR (expanded) spectrum




Figure 4.  $^{13}\text{C}$  NMR spectrum of 2




Figure 5.  $^1\text{H}$  NMR spectrum of 3




Figure 6.  $^{13}\text{C}$  NMR spectrum of 3

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGMENTS

The encouragement and support from Bharath University, Chennai is gratefully acknowledged. For provided the laboratory facilities to carry out the research work.

## REFERENCES

- [1]. F. Felluga, V. Gombac, G. Pitacco, E. Valentin, E. Zangrando, S. Morganti, E. Rizzato, D. Spinelli, G. Petrillo, *Tetrahedron* 2006, 62, 8787 – 8791.
- [2]. Singh, P.; Dimitriou, V.; Malajan, R.P.; Crossley, A.W. Double-blind comparison between doxapram and pethidine in the treatment of postanaesthetic shivering. *Br. J. Anaesth.* 1993, 71, 685–688.
- [3]. Winbal, B. Piracetam: A review of pharmacological properties and clinical uses. *CNS Drug Rev.* 2005, 11, 169–182
- [4]. Panday, S.K.; Prasad, J.; Dikshit, K.D. Pyroglutamic acid: A unique chiral synthon. *Tetrahedron: Asymmetry* 2009, 20, 1581–1632.
- [5]. Coppola, G.M.; Schuster, H.F. *Asymmetric Synthesis. Construction of Chiral Molecules Using Amino Acids*; John Wiley: New York, NY, USA, 1987
- [6]. Moutevelis-Minakakis, P.; Papavassilopoulou, E.; Michas, G.; Georgikopoulou, K.; Ragoussi, M.E.; Neophytou, N.; Zoumpoulakis, P.; Mavromoustakos, T.; Hadjipavlou-Litina, D. *Bioorg. Med. Chem.* 2011, 19, 2888–2902.
- [7]. Mavromoustakos, T.; Moutevelis-Minakakis, P.; Kokotos, C.G.; Kontogianni, P.; Politi, A.; Zoumpoulakis, P.; Findlay, A.; Cox, A.; Balmforth, A.; Zoga, A. *Bioorg. Med. Chem.* 2006, 14, 4353–4360.
- [8]. Mavromoustakos, T.; Fotakis, C.; Siapi, E.; Potamitis, C.; Viras, K.; Moutevelis-Minakakis, P.; Kokotos, G.; Durgasi, S.; Grdadolnik, S.; Sartori, B *BBA-Biomembranes*, 2010, 1798, 422–432.
- [9]. Panday, S.K.; Prasad, J.; Dikshit, K.D. Pyroglutamic acid: A unique chiral synthon. *Tetrahedron: Asymmetry* 2009,20, 1581–1632
- [10]. Moutevelis-Minakakis, P.; Gianni, M.; Stougiannou, H.; Zoumpoulakis, P.; Zoga, A.; Vlahakos, E.; Iliodromitis, E.; Mavromoustakos, *Bioorg. Med. Chem. Lett.* 2003, 13, 1737–1740.

## Cite this article as :

Veerappan Jeyachandran, "Synthesis, Characterization and Biological Activate 5-(Hydroxymethyl) Pyrrolidin-2-One at Room Temperature", *International Journal of Scientific Research in Science and Technology (IJSRST)*, Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 8 Issue 1, pp. 10-15, January-February 2021. Available at doi : <https://doi.org/10.32628/IJSRST207668>  
Journal URL : <http://ijsrst.com/IJSRST207668>